CAR-T Therapy Shows Promise in HIV Fight: Small Study Finds Two Patients Achieved Long-Term Virus Suppression

In a breakthrough that could reshape the battle against HIV, scientists are borrowing a powerful cancer-fighting tool and testing whether it might help the body control the virus that causes AIDS. Early research presented this week suggests that a single dose of specially engineered immune cells kept the virus at undetectable levels in two patients for nearly two years—without the need for their daily HIV medications.

The findings, while preliminary, offer a glimmer of hope for the nearly 40 million people living with HIV worldwide. But experts caution that much more research is needed before this approach could become a widely available treatment or cure.

What Did the Study Actually Find?

Researchers from the University of California San Francisco and the nonprofit drug developer Caring Cross tested a therapy known as chimeric antigen receptor (CAR) T-cell therapy. This treatment is already a proven weapon against certain blood cancers. For this HIV study, scientists took T cells—a type of immune cell—from patients’ blood, genetically modified them in a lab, and then infused them back into the patients.

The results, presented Tuesday at the American Society of Gene and Cell Therapy meeting in Boston, showed that two out of nine participants had a strong and lasting response. One patient saw HIV suppressed for nearly a year, and the other for nearly two years—without taking their usual antiretroviral drugs. A third patient had a temporary response and later resumed regular treatment.

Dr. Steven Deeks, who led the research, described the outcome as “provocative.” He noted that the two strong responders had started their original HIV treatment soon after they were first infected. This is significant because people who begin treatment early tend to have less HIV hiding in the body and a healthier immune system overall.

However, the first three participants in the study showed no response at all and had to restart their medications. Six others received a small amount of chemotherapy before the CAR-T infusion to make room for the new cells. Among those, two had the strong response, one had a temporary response, and the remaining three did not respond.

How Does This CAR-T Therapy Work for HIV?

CAR-T therapy is often described as creating “living drugs.” Doctors collect a patient’s T cells, reprogram them in a lab to recognize and attack a specific target, and then put them back into the bloodstream. In cancer treatment, those targets are tumor cells. For HIV, the target is different.

The CAR-T cells used in this study were designed with two special features. First, they were programmed to better find and kill cells infected with HIV. Second, they were engineered with a protective shield that prevents them from being infected by the very virus they are supposed to fight. This is a crucial improvement, because HIV normally attacks and destroys T cells.

Dr. Boro Dropulić, executive director of Caring Cross, explained that this added armor should allow the CAR-T cells to reproduce and keep the virus in check over the long term. In the two patients who responded well, their HIV levels dropped to undetectable levels. Occasionally, the virus would inch back up—likely when the CAR-T cells were being reactivated to fight again.

Why Is This Different from Current HIV Treatments?

Today’s standard HIV medicines, known as antiretroviral therapy (ART), are highly effective. They can reduce the virus to undetectable levels, prevent transmission to others, and allow people with HIV to live long, healthy lives. But there is a catch: patients must take these drugs every day for the rest of their lives. If they stop, the virus rebounds quickly from hidden reservoirs in the body.

This is a major challenge. Many people around the world cannot afford or reliably access daily medications. Even in wealthy countries, sticking to a lifelong daily pill regimen can be difficult. The goal of a “one-and-done” treatment—a single therapy that controls HIV for years or even cures it—has been a top priority for researchers for decades.

Dr. Deeks summed up the need clearly: “There is a real need for a one-and-done, safe, and scalable cure.” CAR-T therapy, if proven effective, could potentially offer that kind of long-lasting control.

What Do Experts Say About This Approach?

The scientific community is watching these results with cautious optimism. Dr. Hans-Peter Kiem, a gene therapy expert at Seattle’s Fred Hutchinson Cancer Center who was not involved in the study, called the findings “very fascinating.” However, he stressed that larger and longer studies are needed to prove whether CAR-T therapy truly works for HIV.

Andrea Gramatica, vice president for research at amfAR, the Foundation for AIDS Research, said the strategy is exciting because it is “boosting what our body, our immune system, can already do.” Her organization is funding work to create easier-to-use versions of this therapy, which could make it more accessible in the future.

It is important to note that this is not the first attempt to cure HIV. Previous efforts have explored rare gene mutations that make some people naturally resistant to the virus. There have also been a handful of cases where HIV patients who had certain cancers were declared cured or in long-term remission after receiving a stem cell transplant. However, those transplants are risky, expensive, and not suitable for most people.

How Could This Affect People Living with HIV?

For the nearly 40 million people living with HIV globally, the idea of a single treatment that could replace daily pills is life-changing. It could reduce the burden of remembering to take medication, lower healthcare costs, and improve quality of life. It could also help reach populations in remote or low-income areas where access to daily drugs is limited.

However, it is critical to manage expectations. This study involved only nine people. The therapy is still experimental, and it is not ready for widespread use. The two strong responders were people who started HIV treatment early—a scenario that may not apply to everyone living with the virus. Additionally, the need for chemotherapy before the infusion adds complexity and potential side effects.

No serious side effects were reported in this small study, but larger trials will need to carefully monitor safety. The patients who did not respond highlight that this therapy is not a guaranteed solution for everyone.

Practical Takeaways for Readers

While this research is promising, here is what you need to know right now:

• Current HIV treatments remain effective. If you or someone you know is living with HIV, daily antiretroviral therapy is still the gold standard. Do not stop taking medication without a doctor’s guidance.
• This therapy is not available yet. CAR-T for HIV is in early-stage testing. It will take years of additional research, including larger trials, before it could be approved by regulators.
• Early treatment matters. The study suggests that people who start HIV treatment soon after infection may have better immune health and could be stronger candidates for future therapies.
• Stay informed. Follow trusted sources like the National Institutes of Health, the Centers for Disease Control and Prevention, and reputable health news outlets for updates on HIV research.
• Support research. Organizations like amfAR are funding innovative work to make these treatments simpler and more accessible. Public awareness and funding can accelerate progress.

What Comes Next?

Dr. Deeks and his team plan to conduct larger and longer studies to confirm whether CAR-T therapy can provide durable HIV control. They will also explore why some patients responded and others did not. Scientists at Caring Cross are working to refine the design of the CAR-T cells to make them more effective and easier to produce.

Experts agree that a true cure for HIV—one that completely eliminates the virus from the body—remains elusive. But this study suggests that a functional cure, where the immune system can keep the virus in check without daily medication, may be within reach. For now, the world waits for more data, while the two patients in this study continue to live without their usual HIV medicines, their bodies holding the virus at bay thanks to a single dose of revved-up immune cells.

Source: MedPage Today